The Journal of Clinical Pharmacology最新文献

筛选
英文 中文
Beyond Class-Wide Warnings: A Dynamic Framework for Infection Vulnerability During Complement-Directed Therapy in Paroxysmal Nocturnal Hemoglobinuria 超越类别范围的警告:在补体指导治疗阵发性夜间血红蛋白尿期间感染脆弱性的动态框架。
The Journal of Clinical Pharmacology Pub Date : 2026-11-06 DOI: 10.1002/jcph.70331
Yutaka Shimazu MD, PhD, Shojiro Inano MD, PhD, Daiki Hira PhD
{"title":"Beyond Class-Wide Warnings: A Dynamic Framework for Infection Vulnerability During Complement-Directed Therapy in Paroxysmal Nocturnal Hemoglobinuria","authors":"Yutaka Shimazu MD, PhD, Shojiro Inano MD, PhD, Daiki Hira PhD","doi":"10.1002/jcph.70331","DOIUrl":"10.1002/jcph.70331","url":null,"abstract":"<p>Complement-directed therapies have transformed the management of paroxysmal nocturnal hemoglobinuria (PNH), but they also alter host defense against encapsulated bacteria, particularly <i>Neisseria meningitidis</i>. Public health and regulatory guidance therefore recommend meningococcal vaccination and continued clinical vigilance, because invasive disease can still occur despite vaccination. Current US guidance explicitly includes both C5 inhibitors and inhibitors of other complement components, while emphasizing that the most mature evidence for breakthrough meningococcal disease comes from C5 inhibition. In Japan, the Japanese Society of Hematology issued a renewed safety alert in September 2026 covering multiple complement inhibitors and recommending rapid evaluation and empiric antimicrobial treatment when compatible symptoms occur.<span><sup>1, 2</sup></span></p><p>Such broad warnings are appropriate for emergency care, where the cost of missing invasive meningococcal disease is high. However, class-wide vigilance should not be interpreted as pharmacological equivalence across complement-directed therapies. As the therapeutic landscape expands from terminal C5 blockade to proximal inhibition at C3 (pegcetacoplan), complement factor B (iptacopan), and complement factor D (danicopan), the relevant question is not which agent is “safer,” but how different mechanisms of complement inhibition reshape susceptibility to infection in different clinical states.</p><p>Experimental evidence supports this mechanistic heterogeneity. In immunized adults, eculizumab impaired opsonophagocytic killing of meningococci in whole blood; in vaccinated patients with PNH, vaccine-induced antibodies still bound meningococci and initiated complement activation, but C5 blockade prevented membrane-attack-complex formation and completely blocked whole-blood killing under the assay conditions studied.<span><sup>3, 4</sup></span> These findings are best interpreted as marked impairment of complement-dependent meningococcal defense rather than proof that clinical protection is universally absent.</p><p>The effects of more proximal inhibition are different. In serum bactericidal assays, C5 inhibition abrogated meningococcal killing, whereas inhibition of complement factor B (iptacopan) or complement factor D preserved killing in many post-vaccination sera, particularly when bactericidal antibody activity was high. C3 inhibition reduced killing in most, but not all, sera.<span><sup>5, 6</sup></span> These experiments do not establish a clinical safety hierarchy. However, they show that the residual antimicrobial functions of the complement system depend on where and how the pathway is inhibited. As with other adverse-event profiles, susceptibility to particular infections may therefore differ according to the pharmacological mechanism.</p><p>Clinical observations are consistent with this mechanistic distinction, although direct comparisons are limited. The largest accumu","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.70331","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bringing Innovation in Bioequivalence Studies: Evaluating Multiple Test Formulations in a Single Crossover Pivotal Bioequivalence Study Using Multiplicity Correction 在生物等效性研究中带来创新:在单一交叉关键生物等效性研究中使用多重校正评估多个试验配方
The Journal of Clinical Pharmacology Pub Date : 2026-11-02 DOI: 10.1002/jcph.70325
Chandra Teja Uppuluri PhD, Rajkumar Boddu PhD, Sohel Mohammed Khan MSc, Anuj Kumar Saini PhD, Sivacharan Kollipara PhD
{"title":"Bringing Innovation in Bioequivalence Studies: Evaluating Multiple Test Formulations in a Single Crossover Pivotal Bioequivalence Study Using Multiplicity Correction","authors":"Chandra Teja Uppuluri PhD,&nbsp;Rajkumar Boddu PhD,&nbsp;Sohel Mohammed Khan MSc,&nbsp;Anuj Kumar Saini PhD,&nbsp;Sivacharan Kollipara PhD","doi":"10.1002/jcph.70325","DOIUrl":"https://doi.org/10.1002/jcph.70325","url":null,"abstract":"<p>ICH M13A recognizes higher-order bioequivalence (BE) studies involving multiple test or comparator products. When any one of several test formulations may independently demonstrate BE and support subsequent selection, multiplicity adjustment is required to control the family-wise type I error rate. This requirement introduces a practical penalty through increased sample-size requirements, wider confidence intervals, and a narrower range of test-to-reference geometric mean ratios that would result in BE conclusions. Although the statistical foundations of multiplicity correction are well established, the available literature has focused predominantly on methodological procedures, with limited consideration of the practical questions encountered during pharmaceutical product development. This review briefly summarizes the regulatory and statistical background and presents a scenario-based evaluation of the consequences of multiplicity in multi-formulation crossover BE studies. Analytical assessments were used to quantify sample-size inflation, confidence interval widening, and contraction of the T/R range that would result in a BE conclusion. Simulated BE study datasets complemented these evaluations, analyzed using full-data pooled-MSE (mean squared error) and separate pairwise ANOVA (analysis of variance) approaches and four multiplicity strategies: no adjustment, Bonferroni, Holm, and Hochberg for multiplicity adjustment. The review provides a practical framework for balancing statistical penalty against the value of preserving the ability to retain more than one formulation candidate within a single pivotal study or development. The present evaluation is restricted to non-replicate crossover BE studies.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149310866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating Omics to Advance Antiretroviral Pharmacology in Pregnancy: Dolutegravir-Based Regimens as a Case Study 整合组学以推进妊娠期抗逆转录病毒药理学:以孕酮为基础的治疗方案为案例研究
The Journal of Clinical Pharmacology Pub Date : 2026-11-01 DOI: 10.1002/jcph.70324
Ahizechukwu C. Eke MD, PhD, MPH
{"title":"Integrating Omics to Advance Antiretroviral Pharmacology in Pregnancy: Dolutegravir-Based Regimens as a Case Study","authors":"Ahizechukwu C. Eke MD, PhD, MPH","doi":"10.1002/jcph.70324","DOIUrl":"https://doi.org/10.1002/jcph.70324","url":null,"abstract":"<p>Dolutegravir is central to antiretroviral therapy in pregnancy, although conventional pharmacokinetic measures cannot fully explain variability in maternal cardiometabolic outcomes or fetal exposure. This narrative review proposes an integrated omics framework linking pharmacogenomics, transcriptomics, proteomics, and metabolomics with longitudinal pharmacokinetics and clinical phenotyping. Using dolutegravir as a case study, we examine genetic determinants of drug disposition, gestational changes in molecular pathways, and emerging evidence implicating adipose dysfunction, mitochondrial metabolism, lipid remodeling, and insulin resistance. We distinguish established pharmacokinetic findings from mechanistic hypotheses requiring pregnancy-specific validation. Proposed studies combine serial maternal sampling, targeted placental and adipose investigations, and offspring follow-up, while accounting for HIV, antiretroviral backbone, gestational physiology, and environmental confounding. Prespecified analyses, analytical validation, and independent replication are essential to avoid overinterpretation. Integrated omics should complement, not replace, pharmacometrics, ultimately identifying reproducible mechanisms and clinically useful biomarkers to inform individualized monitoring and treatment strategies while preserving dolutegravir's proven virologic benefits.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.70324","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149310913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physiologically Based Pharmacokinetic Modeling to Predict the Exposure and Provide Dosage Regimens of Oseltamivir in Pregnant Women with Comorbid CES1 Polymorphism and Hepatic Cirrhosis 基于生理的药代动力学模型预测奥司他韦在合并CES1多态性和肝硬化的孕妇中的暴露并提供剂量方案
The Journal of Clinical Pharmacology Pub Date : 2026-11-01 DOI: 10.1002/jcph.70285
Jianwen Xu MS, Shoutian Zhang BS, Peilin Zhou MS, Zhikun Zhan PhD, Shuifang Zhou BS, Yuewen Chen BS, Rongfang Lin MS, Cuihong Lin PhD
{"title":"Physiologically Based Pharmacokinetic Modeling to Predict the Exposure and Provide Dosage Regimens of Oseltamivir in Pregnant Women with Comorbid CES1 Polymorphism and Hepatic Cirrhosis","authors":"Jianwen Xu MS,&nbsp;Shoutian Zhang BS,&nbsp;Peilin Zhou MS,&nbsp;Zhikun Zhan PhD,&nbsp;Shuifang Zhou BS,&nbsp;Yuewen Chen BS,&nbsp;Rongfang Lin MS,&nbsp;Cuihong Lin PhD","doi":"10.1002/jcph.70285","DOIUrl":"https://doi.org/10.1002/jcph.70285","url":null,"abstract":"<p>Oseltamivir (OSE) is widely prescribed for pregnant women with influenza; however, its optimal dosing strategy remains undefined in cases involving carboxylesterase 1 (<i>CES1</i>) gene polymorphism and hepatic cirrhosis. This study aimed to explore OSE dosing regimens for pregnant patients with comorbid <i>CES1</i> polymorphism and hepatic cirrhosis. A mechanistic physiologically based pharmacokinetic (PBPK) model of OSE was first built and verified in healthy populations, then extrapolated to adult patients with <i>CES1</i> polymorphism, hepatic cirrhosis, and pregnant patients. The PBPK model successfully predicted and verified the PKs of OSE and its active metabolite oseltamivir carboxylate (OSC) in both non-pregnant and pregnant women. Simulation results showed that the fold errors of the predicted and observed values of the area under the curve (AUC) and peak plasma concentration (C<sub>max</sub>) values ranged from 0.5 to 2.0, with the average folding error and absolute average folding error for all concentration–time data points reaching 0.89 and 1.38, respectively. Importantly, for pregnant patients, OSE administration is recommended to be tailored by <i>CES1</i> genotype, cirrhosis severity, and pregnancy trimester, to achieve post-dosing AUC levels comparable to those of the non-pregnant reference population. This integrated pregnancy PBPK model enables us to comprehensively and extensively explore the PK characteristics of OSE and OSC in pregnant women under complex scenarios, thereby providing valuable guidance for clinical applications and precise management of influenza during pregnancy.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149310916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population Pharmacokinetic and Pharmacodynamic Model of Propofol in Patients With Chronic Kidney Disease 异丙酚在慢性肾病患者中的群体药动学和药效学模型
The Journal of Clinical Pharmacology Pub Date : 2026-11-01 DOI: 10.1002/jcph.70268
Rachna Rohilla MD, DM, Jaya Shree Dilli Batcha PhD, Preethy Mathew MD, Goverdhan Dutt Puri MD, Surulivelrajan Mallayasamy PhD, Ravimohan S. Mavuduru MS, MCh, Arup Kumar Mandal MS, MCh, Smita Pattanaik MD, DM
{"title":"Population Pharmacokinetic and Pharmacodynamic Model of Propofol in Patients With Chronic Kidney Disease","authors":"Rachna Rohilla MD, DM,&nbsp;Jaya Shree Dilli Batcha PhD,&nbsp;Preethy Mathew MD,&nbsp;Goverdhan Dutt Puri MD,&nbsp;Surulivelrajan Mallayasamy PhD,&nbsp;Ravimohan S. Mavuduru MS, MCh,&nbsp;Arup Kumar Mandal MS, MCh,&nbsp;Smita Pattanaik MD, DM","doi":"10.1002/jcph.70268","DOIUrl":"https://doi.org/10.1002/jcph.70268","url":null,"abstract":"<p>Propofol is a commonly used intravenous anesthetic. Although the kidney plays a minor role in elimination, pharmacokinetics (PK) and pharmacodynamics (PD) have been found to be significantly affected in patients with chronic kidney disease (CKD). The study was a prospective, single-centre study in CKD patients undergoing surgery under general anaesthesia. A total of 9–10 blood samples were collected from each of 38 patients at prespecified sampling time points for propofol quantification. Time to loss of consciousness and time to eye opening were recorded, along with the bispectral index (BIS), as PD endpoints. The concentration time profile (287 samples) and BIS data from 35 patients were included in model development. Creatinine clearance was identified as an important covariate affecting the PK model. Stage 3 and 4 patients achieved higher plasma concentrations at the same induction and maintenance propofol doses and tended to have lower BIS. The propofol <i>C</i><sub>max</sub> was higher in stage 4 patients than in stages 1 or 2. The average concentration at LOC was significantly higher in stage 4 (6.61 ± 6.28 µg/mL) as compared to stages 1 (2.06 ± 1.69 µg/mL) or stage 2 (1.64 ± 1.77 µg/mL). Average time to eye opening was also higher in stages 3 and 4 (12.9 ± 4.7 and 9.5 ± 3.1 min, respectively) as compared to stages 1 and 2 (7 ± 3.2 and 7.9 ± 2.4 min, respectively). The moderate-severe renal impairment status decreases the requirement of the induction dose of propofol to achieve surgical anesthesia compared to those with normal creatinine clearance. Prolonged clearance also leads to prolonged emergence from anesthesia.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149310920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug–Drug Interaction Studies in Drug Development 药物开发中临床药代动力学药物相互作用研究的设计、实施和报告的实际考虑
The Journal of Clinical Pharmacology Pub Date : 2026-11-01 DOI: 10.1002/jcph.70326
Thomas M. Polasek BSc, BPharm (Hons), MD, PhD, FCP, John O. Miners BSc, MSc, PhD, DSc, FAA
{"title":"Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug–Drug Interaction Studies in Drug Development","authors":"Thomas M. Polasek BSc, BPharm (Hons), MD, PhD, FCP,&nbsp;John O. Miners BSc, MSc, PhD, DSc, FAA","doi":"10.1002/jcph.70326","DOIUrl":"https://doi.org/10.1002/jcph.70326","url":null,"abstract":"<p>Clinical pharmacokinetic drug–drug interaction (PK-DDI) studies are frequently required in drug development when metabolizing enzymes and transporters determine pharmacokinetics. Drugs can be victims, perpetrators, or victims and perpetrators, of PK-DDIs, so the clinical consequences of these interactions, particularly the risks of severe adverse effects and therapeutic failures leading to poor clinical outcomes, must be well understood prior to regulatory filings. In this Commentary, background information on PK-DDIs is summarized to the point in drug development where the decision is made to conduct a human study. Practical considerations for the design and conduct of clinical PK-DDI studies are then addressed sequentially, including guidance about study populations, the selection of probe drugs, their doses and durations, suitable study designs, the contentious issues with inclusion and exclusion criteria, which endpoints are the most important, and samples sizes and power estimates. Guidance on how results should be reported is given, including clinical study reports and scientific literature. Although intended primarily for the pharmaceutical industry, the key points apply across all sectors of drug development and are best considered together with regulatory guidelines on drug interaction studies.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.70326","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149310914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics and Safety of Deuremidevir Hydrobromide (JT001) in Subjects with Mild and Moderate Renal Impairment: An Open-Label, Parallel-Group Phase I Study 氢溴化德脲米韦(JT001)在轻度和中度肾功能损害患者中的药代动力学和安全性:一项开放标签、平行组I期研究
The Journal of Clinical Pharmacology Pub Date : 2026-10-25 DOI: 10.1002/jcph.70311
Tong Lu MSc, Xi Tan MSc, Shijuan Kuang MSc, Qin Meng MSc, Ge Yu MSc, Jianjun Zou PhD, MD, Yuya Wang PhD
{"title":"Pharmacokinetics and Safety of Deuremidevir Hydrobromide (JT001) in Subjects with Mild and Moderate Renal Impairment: An Open-Label, Parallel-Group Phase I Study","authors":"Tong Lu MSc,&nbsp;Xi Tan MSc,&nbsp;Shijuan Kuang MSc,&nbsp;Qin Meng MSc,&nbsp;Ge Yu MSc,&nbsp;Jianjun Zou PhD, MD,&nbsp;Yuya Wang PhD","doi":"10.1002/jcph.70311","DOIUrl":"https://doi.org/10.1002/jcph.70311","url":null,"abstract":"<p>JT001 (deuremidevir hydrobromide, VV116) is an oral antiviral prodrug that is rapidly converted in vivo to its active metabolite, 116-N1. Since 116-N1 is mainly cleared by the kidneys, renal impairment may increase its systemic exposure. This study evaluated the pharmacokinetics of 116-N1 following a single 0.3-g oral dose of JT001 in participants with mild or moderate renal impairment and matched healthy controls. Absorption was generally similar across groups, with comparable time to peak concentration. However, declining renal function increased exposure to 116-N1 and slowed its elimination. Terminal half-life increased from 5.31 to 8.13 and 11.2 h in mild and moderate impairment. Apparent oral clearance decreased from 34.3 L/h in healthy participants to 21.4 and 13.8 L/h in patients with mild and moderate renal impairment, respectively. Twenty-four participants (eight per renal function group) were enrolled. Geometric mean AUC<sub>0–t</sub> increased by 63% in participants with mild renal impairment (geometric mean ratio [GMR] 163.31%, 90% CI 135.99%–196.12%) and by 157% in those with moderate renal impairment (GMR 257.42%, 90% CI 214.35%–309.13%), whereas C<sub>max</sub> remained comparable between groups. JT001 was generally well tolerated, with no serious or grade ≥3 treatment-related adverse events. To further assess clinical relevance of these findings, the renal impairment data were incorporated into an updated population pharmacokinetic model. Simulations suggested that the approved regimen was suitable for patients with mild renal impairment, whereas a reduced regimen of 300 mg twice daily on Day 1 followed by 200 mg twice daily on Days 2–5 was recommended for patients with moderate renal impairment.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149259094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to “Beyond Fortnightly Convenience: A VALIDATE Pathway for TE-8105 in Global Obesity Care” 回复“超越两周便利:TE-8105在全球肥胖护理中的验证途径”。
The Journal of Clinical Pharmacology Pub Date : 2026-10-22 DOI: 10.1002/jcph.70317
Ya-Shan Chuang BSc, PhD, Jon D. Wright BSc (Hons), PhD, Mun-Teng Wong BHSc (Hons), PhD, Kushal J. Paneliya BHSc, Wei-Shiung Yang MD, PhD, Hsing-Mao Chu BSc, PhD, Tse Wen Chang BSc, MSc, PhD, Thomas M Polasek BSc, BPharm (Hons), MD, PhD, FCP
{"title":"Reply to “Beyond Fortnightly Convenience: A VALIDATE Pathway for TE-8105 in Global Obesity Care”","authors":"Ya-Shan Chuang BSc, PhD,&nbsp;Jon D. Wright BSc (Hons), PhD,&nbsp;Mun-Teng Wong BHSc (Hons), PhD,&nbsp;Kushal J. Paneliya BHSc,&nbsp;Wei-Shiung Yang MD, PhD,&nbsp;Hsing-Mao Chu BSc, PhD,&nbsp;Tse Wen Chang BSc, MSc, PhD,&nbsp;Thomas M Polasek BSc, BPharm (Hons), MD, PhD, FCP","doi":"10.1002/jcph.70317","DOIUrl":"10.1002/jcph.70317","url":null,"abstract":"&lt;p&gt;To the Editor&lt;/p&gt;&lt;p&gt;We thank Jayaswal and colleagues for their letter about our first-in-human trial with TE-8105, a novel long-acting GLP-1 receptor agonist.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; They correctly say that the clinical utility of TE-8105 will depend on much more than just decreasing the SC injection burden from once weekly to once every 2 weeks or longer. Whether TE-8105 translates into a favorable benefit–risk profile with good patient-reported outcomes (e.g., treatment satisfaction) will be determined in the larger clinical trials. Our report is just the first step.&lt;/p&gt;&lt;p&gt;Their letter proposes a VALIDATE acronym to address some of the key challenges facing the clinical development of TE-8105. We think VALIDATE has relevance to clinical pharmacology more broadly, not just for TE-8105, as explained here.&lt;/p&gt;&lt;p&gt;Clinical pharmacologists should determine the covariates contributing to between-patient variability (&lt;b&gt;&lt;span&gt;V&lt;/span&gt;&lt;/b&gt;) in drug exposures, and whether these have meaningful pharmacodynamic consequences to be accounted for in drug labeling. A good example is pharmacogenomics, which can, albeit rarely, be important for safe prescribing.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Potentially dangerous accumulation (&lt;b&gt;&lt;span&gt;A&lt;/span&gt;&lt;/b&gt;) of drugs is identified in dose-escalation studies that focus on pharmacokinetic and safety and tolerability endpoints.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Particular attention is required by clinical pharmacologists to ensure safe starting doses and adequate dose ranges. Long-term benefit–risk (&lt;b&gt;&lt;span&gt;L&lt;/span&gt;&lt;/b&gt;) must be addressed throughout a drug's lifecycle, including with post-marketing pharmacovigilance to identify rare associations.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Extension studies following Phase 3 are common-place for new anti-obesity drugs. These provide further benefit–risk data, particularly about weight maintenance and rebound, muscle mass changes, and uncommon adverse effects such as pancreatitis. Derisking for drug–drug interactions (&lt;b&gt;&lt;span&gt;I&lt;/span&gt;&lt;/b&gt;) starts in non-clinical development and may require clinical studies.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Mechanistic understanding of drug–drug interactions is essential for clinical pharmacologists, together with competence in the utility of in vitro–in vivo extrapolation (IVIVE) approaches and their limitations.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; Increasing the diversity (&lt;b&gt;&lt;span&gt;D&lt;/span&gt;&lt;/b&gt;) of clinical trial participants is now a regulatory priority,&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; bridging the gap between trial populations and real-world patients.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; Clinical pharmacologists determine when bridging studies are needed and how to enrich patient populations most efficiently. The second letter &lt;b&gt;&lt;span&gt;A&lt;/span&gt;&lt;/b&gt; stands for adherence in the acronym, but could equally apply to administration, a word that covers all factors determining whether drugs are actually taken by patients.&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; Up-and-down dose titration (&lt;b&gt;&lt;span&gt;T&lt;/span&gt;&lt;/b&gt;) of GLP-1 rece","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.70317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149247072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond Fortnightly Convenience: A VALIDATE Pathway for TE-8105 in Global Obesity Care 超越两周便利:TE-8105在全球肥胖护理中的验证途径。
The Journal of Clinical Pharmacology Pub Date : 2026-10-22 DOI: 10.1002/jcph.70320
Rajesh Prasad Jayaswal PhD, Pranay P. Pankaj PhD, Shikha Thapa MMLS, Mhaveer Singh PhD
{"title":"Beyond Fortnightly Convenience: A VALIDATE Pathway for TE-8105 in Global Obesity Care","authors":"Rajesh Prasad Jayaswal PhD,&nbsp;Pranay P. Pankaj PhD,&nbsp;Shikha Thapa MMLS,&nbsp;Mhaveer Singh PhD","doi":"10.1002/jcph.70320","DOIUrl":"10.1002/jcph.70320","url":null,"abstract":"&lt;p&gt;Chuang et al provide timely first-in-human evidence for TE-8105, a long-acting glucagon-like peptide-1 receptor agonist intended for fortnightly administration.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; A half-life of approximately 120 h and acceptable short-term tolerability support continued development. Yet the clinically decisive signal is not dosing freqency alone. In the titration cohort, mean end-of-study weight reduction was 2.06%, four of eight participants maintained at least 5% loss, and exposure accumulated three- to fourfold; the flat-dose cohort gained weight. These findings appropriately establish feasibility, not comparative efficacy.&lt;/p&gt;&lt;p&gt;Fortnightly dosing could reduce injection burden, but convenience should be tested rather than assumed to improve persistence. Real-world 1-year persistence with glucagon-like peptide-1 therapies for obesity has been low,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; while semaglutide outcome data show that durable clinical value depends on sustained treatment.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; TE-8105 may therefore be most useful if its longer interval improves persistence without amplifying peak-related gastrointestinal toxicity, delayed recognition of intolerance, or prolonged recovery after adverse effects. Its effect on gastric emptying and absorption of narrow-therapeutic-index drugs also warrants direct study; class evidence identifies this as a plausible interaction pathway.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;We propose a VALIDATE pathway: Variability in exposure across body size, renal and hepatic function, and ancestry; Accumulation and dose proportionality using population pharmacokinetic modeling; Long-term benefit–risk against an active weekly comparator; Interaction testing with oral contraceptives and other time-critical oral medicines; Diversity across diabetes status, sex, age, ethnicity, and obesity severity; Adherence and patient-reported treatment burden; Titration and missed-dose rules informed by exposure–response; and Equitable access, including device usability, cold-chain resilience, and cost. The observed nonlinear exposure makes model-informed dose selection and prespecified exposure–response thresholds especially important before larger efficacy trials.&lt;/p&gt;&lt;p&gt;Future trials should be randomized, blinded, adequately powered, and long enough to assess weight loss, weight regain after interruption, cardiometabolic outcomes, lean-mass preservation, antidrug antibodies, pancreatic and biliary events, and discontinuation. Enrollment should extend beyond predominantly healthy White participants at one Australian site to people with type 2 diabetes, metabolic dysfunction–associated steatotic liver disease, chronic kidney disease, polypharmacy, and populations in low- and middle-income countries. Access planning should begin during development: Glucagon-like peptide-1 therapies remain inequitably available,&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; despite evidence that sustainable manufacturing-based prices can be far below prevailing mark","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.70320","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149247090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population Pharmacokinetic Analysis of Tacrolimus in Time-Dependent Increase of Clearance for Patients with Living-Donor Liver Transplantation: A Prospective Observational Study 他克莫司对活体肝移植患者清除率随时间增加的人群药代动力学分析:一项前瞻性观察研究。
The Journal of Clinical Pharmacology Pub Date : 2026-10-22 DOI: 10.1002/jcph.70315
Naoya Matsumoto MS, Kazutaka Oda PhD, Keita Shimata PhD, Kazuya Hirukawa PhD, Yuto Sakurai PhD, Taizo Hibi PhD, Hirofumi Jono PhD, Hideyuki Saito PhD
{"title":"Population Pharmacokinetic Analysis of Tacrolimus in Time-Dependent Increase of Clearance for Patients with Living-Donor Liver Transplantation: A Prospective Observational Study","authors":"Naoya Matsumoto MS,&nbsp;Kazutaka Oda PhD,&nbsp;Keita Shimata PhD,&nbsp;Kazuya Hirukawa PhD,&nbsp;Yuto Sakurai PhD,&nbsp;Taizo Hibi PhD,&nbsp;Hirofumi Jono PhD,&nbsp;Hideyuki Saito PhD","doi":"10.1002/jcph.70315","DOIUrl":"10.1002/jcph.70315","url":null,"abstract":"<p>Tacrolimus is a first-line immunosuppressant used to prevent rejection in living donor liver transplantation (LDLT) and is subject to therapeutic drug monitoring due to its concentration-dependent effects and side effects. Metabolism of tacrolimus is reduced by the CYP3A5*3 allele. In addition, liver regeneration over time leads to increased tacrolimus clearance. The purpose of this study was to develop a tacrolimus population pharmacokinetic (popPK) model that takes into consideration the CYP3A5*3 allele and the time-dependent increase in clearance. To develop the popPK model, we used data from 25 recipients and 25 donors who received LDLT and tacrolimus at Kumamoto University Hospital. The measured data consisted of four blood concentration points including peak values at 12 h after the first dose of tacrolimus, and trough blood concentrations obtained by TDM on consecutive days. Nonlinear mixed-effects modeling method was used to develop the popPK model, and i-Densy by ARKRAY Co., Ltd. was used for CYP3A5 gene polymorphism analysis. The popPK model was developed as a one-compartment model incorporating a time-dependent sigmoidal model for clearance. Total bilirubin value was found to be a predictor of volume of distribution and rate constant of absorption, while aspartate transaminase was found to be a predictor of volume of distribution. The CYP3A5*3 allele was not found to be a predictor of tacrolimus pharmacokinetics. We developed a popPK model that includes a time-dependent increase in CL of tacrolimus for patients with LDLT.</p>","PeriodicalId":22751,"journal":{"name":"The Journal of Clinical Pharmacology","volume":"66 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149247100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书